Teijin Of Japan To Do Own Development, Marketing In Asia
This article was originally published in PharmAsia News
Executive Summary
Japan's Teijin Pharma is abandoning its licensing-development course and turning to more direct involvement in developing and selling drugs in Asia. The company has been marketing drugs in China since 2006, but now plans clinical trials in China and Thailand for a new gout drug it plans to market throughout Asia. The drug TMX-67 (febuxostat) has been licensed to a South Korean firm for marketing in that country, but Teijin plans to develop and market the drug by itself in the rest of Asia, where it expects the drug to become a best-seller. Teijin also makes and markets medical equipment. (Click here for more - a subscription may be required